Company overview
Atara Biotherapeutics develops off-the-shelf, allogeneic T-cell immunotherapies targeting cancer, autoimmune diseases, and viral conditions using its EBV T-cell platform. Key pipeline assets include tab-cel® (tabelecleucel) in Phase 3 for EBV+ post-transplant lymphoproliferative disease and ATA3219, an anti-CD19 CAR T therapy. The company has commercialization partnerships, such as with Pierre Fabre for tab-cel® in Europe, Middle East, Africa, and select emerging markets.
Atara is listed in the NovaPharmaNews Supplier Hub in the life-science supply chain serving United States & Americas. Core focus areas include allogeneic t-cell therapy, car t immunotherapy, ebv t-cell platform, tab-cel tabelecleucel, atara biotherapeutics.
Structured facts
- Website
- https://www.atarabio.com
- Markets served
- United States & Americas
- Keywords
- allogeneic t-cell therapy, car t immunotherapy, ebv t-cell platform, tab-cel tabelecleucel, atara biotherapeutics
Products & technologies
Therapeutic areas
Markets served
Company timeline
- — Profile published on NovaPharmaNews
- — Profile last updated
Frequently asked questions
- What are Atara Biotherapeutics' key therapeutic capabilities?
- Atara specializes in off-the-shelf allogeneic T-cell immunotherapies for cancer, autoimmune diseases, and viral conditions, leveraging an EBV T-cell platform with assets like tab-cel® for EBV+ PTLD and ATA3219 anti-CD19 CAR T.
- What is the regulatory status of Atara's lead product tab-cel®?
- Tab-cel® (tabelecleucel) is in Phase 3 for EBV+ post-transplant lymphoproliferative disease and earlier stages for other EBV-associated malignancies; Atara is the first to receive approval for an allogeneic T-cell immunotherapy.
- In which geographies does Atara commercialize its therapies?
- Atara retains rights in North America, Asia Pacific, and Latin America for tab-cel®; Pierre Fabre handles commercialization in Europe, Middle East, Africa, and select emerging markets, with Atara providing manufacturing services.
Related editorial coverage
- Atara Biotherapeutics Receives FDA Complete Response Letter for EBVALLO Cancer Treatment, Faces Securities Class Action
- Atara Biotherapeutics Faces Securities Class Action Lawsuit with May 2026 Deadline for Lead Plaintiff Applications
- FDA Issues Complete Response Letter for Atara Biotherapeutics' EBVALLO Cancer Treatment, Triggering Securities Lawsuit
Explore lab tools and QA/QC resources for R&D teams.
